Drug intelligence / Profile preview

RXDX-108

Development stage: Unknown
Lead developer: Teva Pharmaceutical Industries
Modality: Small Molecules

Overview

**RXDX-108** is a potent, selective small molecule inhibitor of the atypical protein kinase C iota (PKCiota), targeting DNA repair pathways in cancer cells. Developed initially by Teva Pharmaceutical Industries and acquired by Ignyta (a Roche subsidiary) in collaboration with Cancer Research Technology, it was part of Ignyta's precision oncology pipeline aimed at molecularly targeted therapies for solid tumors. The program advanced to preclinical studies but did not progress to clinical trials, with no further development reported after 2015.

Targets

PRKCZ (Protein kinase C zeta)PRKCI (Protein kinase C iota)

Beyond the preview

Go deeper on RXDX-108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RXDX-108.

Explore the full profile